



**Milestone**<sup>TM</sup>  
PHARMACEUTICALS

## Milestone Pharmaceuticals to Present at Upcoming Investor Conferences

March 1, 2022

MONTREAL and CHARLOTTE, N.C., March 1, 2022 /PRNewswire/ -- Milestone Pharmaceuticals Inc. (Nasdaq: MIST), a biopharmaceutical company focused on the development and commercialization of innovative cardiovascular medicines, today announced that members of management will present at the following investor conferences:

- The Cowen 42<sup>nd</sup> Annual Health Care Conference on Tuesday, March 8, 2022 at 2:10 p.m. ET.
- The Oppenheimer 32<sup>nd</sup> Annual Healthcare Conference on Wednesday, March 16, 2022 at 11:20 a.m. ET.

A live webcast of each presentation can be accessed in the News & Events section of Milestone's website at [www.milestonepharma.com](http://www.milestonepharma.com). An archived replay of each webcast will be available on the same website for approximately 90 days following the presentation.

### About Milestone Pharmaceuticals

Milestone Pharmaceuticals Inc. (Nasdaq: MIST), is a biopharmaceutical company focused on the development and commercialization of innovative cardiovascular medicines. Milestone's lead product candidate etripamil is currently in a Phase 3 clinical-stage program for the treatment of paroxysmal supraventricular tachycardia (PSVT) and in a Phase 2 proof-of-concept trial for the treatment of patients with atrial fibrillation and rapid ventricular rate (AFib-RVR). Milestone Pharmaceuticals operates in Canada and the United States. For more information, visit [www.milestonepharma.com](http://www.milestonepharma.com) and follow the Company on Twitter at @MilestonePharma.

### Contact

David Pitts  
Argot Partners  
212-600-1902  
[david@argotpartners.com](mailto:david@argotpartners.com)



**Milestone**<sup>TM</sup>  
PHARMACEUTICALS

 View original content to download multimedia: <https://www.prnewswire.com/news-releases/milestone-pharmaceuticals-to-present-at-upcoming-investor-conferences-301491773.html>

SOURCE Milestone Pharmaceuticals, Inc.